Literature DB >> 20876821

How innate immune mechanisms contribute to antibody-enhanced viral infections.

Sukathida Ubol1, Scott B Halstead.   

Abstract

Preexisting antibodies may enhance viral infections. In dengue, nonneutralizing antibodies raised by natural infection with one of four dengue viruses (DENVs) may enhance infection with a different virus by a process we term "intrinsic antibody-dependent enhancement" (iADE). In addition, nonprotective antibodies raised by formalin-inactivated respiratory syncytial virus (RSV) and measles virus vaccines have led to enhanced disease during breakthrough infections. Infections under iADE conditions not only facilitate the process of viral entry into monocytes and macrophages but also modify innate and adaptive intracellular antiviral mechanisms, suppressing type 1 interferon (IFN) production and resulting in enhanced DENV replication. The suppression observed in vitro has been documented in patients with severe (dengue hemorrhagic fever [DHF]) but not in patient with mild (dengue fever [DF]) secondary dengue virus infections. Important veterinary viral infections also may exhibit iADE. It is thought that use of formalin deconforms viral epitopes of RSV, resulting in poor Toll-like receptor (TLR) stimulation; suboptimal maturation of dendritic cells with reduced production of activation factors CD40, CD80, and CD86; decreased germinal center formation in lymph nodes; and the production of nonprotective antibodies. These antibodies fail to neutralize RSV, allowing replication with secondary stimulation of RSV-primed Th2 cells producing more low-avidity antibody, resulting in immune complexes deposited into affected tissue. However, when formalin-inactivated RSV was administered with a TLR agonist to mice, they were protected against wild-type virus challenge. Safe and effective vaccines against RSV/measles virus and dengue virus may benefit from a better understanding of how innate immune responses can promote production of protective antibodies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20876821      PMCID: PMC3008185          DOI: 10.1128/CVI.00316-10

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  81 in total

1.  ENHANCEMENT OF THE INFECTIVITY OF ARBOVIRUSES BY SPECIFIC ANTISERA PRODUCED IN DOMESTIC FOWLS.

Authors:  R A HAWKES
Journal:  Aust J Exp Biol Med Sci       Date:  1964-08

2.  Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins.

Authors:  Wieslawa Olszewska; Yasemin Suezer; Gerd Sutter; Peter J M Openshaw
Journal:  Vaccine       Date:  2004-11-25       Impact factor: 3.641

3.  Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release.

Authors:  W E Robinson; D C Montefiori; D H Gillespie; W M Mitchell
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

4.  Critical roles for both STAT1-dependent and STAT1-independent pathways in the control of primary dengue virus infection in mice.

Authors:  Sujan Shresta; Kristin L Sharar; Daniil M Prigozhin; Heidi M Snider; P Robert Beatty; Eva Harris
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

Review 5.  Innate immune responses to dengue virus.

Authors:  Erika Navarro-Sánchez; Philippe Desprès; Leticia Cedillo-Barrón
Journal:  Arch Med Res       Date:  2005 Sep-Oct       Impact factor: 2.235

6.  Protection against Japanese encephalitis by inactivated vaccines.

Authors:  C H Hoke; A Nisalak; N Sangawhipa; S Jatanasen; T Laorakapongse; B L Innis; S Kotchasenee; J B Gingrich; J Latendresse; K Fukai
Journal:  N Engl J Med       Date:  1988-09-08       Impact factor: 91.245

7.  Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients.

Authors:  Lien-Cheng Chen; Huan-Yao Lei; Ching-Chuan Liu; Shu-Chu Shiesh; Shun-Hua Chen; Hsiao-Sheng Liu; Yee-Shin Lin; Shan-Tair Wang; Huey-Wen Shyu; Trai-Ming Yeh
Journal:  Am J Trop Med Hyg       Date:  2006-01       Impact factor: 2.345

8.  Evaluation of the 1954 poliomyelitis vaccine field trial; further studies of results determining the effectiveness of poliomyelitis vaccine (Salk) in preventing paralytic poliomyelitis.

Authors:  T FRANCIS
Journal:  J Am Med Assoc       Date:  1955-08-06

9.  Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus.

Authors:  G A Prince; A B Jenson; V G Hemming; B R Murphy; E E Walsh; R L Horswood; R M Chanock
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

10.  Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.

Authors:  B R Murphy; E E Walsh
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

View more
  58 in total

1.  A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.

Authors:  Meagan Bolles; Damon Deming; Kristin Long; Sudhakar Agnihothram; Alan Whitmore; Martin Ferris; William Funkhouser; Lisa Gralinski; Allison Totura; Mark Heise; Ralph S Baric
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

Review 2.  Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.

Authors:  Mario Lobigs; Michael S Diamond
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

Review 3.  Convalescent plasma: new evidence for an old therapeutic tool?

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giuseppina Facco; Liviana Catalano; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-11-06       Impact factor: 3.443

4.  Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.

Authors:  Wahala M P B Wahala; Claire Huang; Siritorn Butrapet; Laura J White; Aravinda M de Silva
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

Review 5.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? There Is Only One True Winner.

Authors:  Scott B Halstead
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

Review 6.  Immunological mechanisms of vaccination.

Authors:  Bali Pulendran; Rafi Ahmed
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

Review 7.  Type I and type II Fc receptors regulate innate and adaptive immunity.

Authors:  Andrew Pincetic; Stylianos Bournazos; David J DiLillo; Jad Maamary; Taia T Wang; Rony Dahan; Benjamin-Maximillian Fiebiger; Jeffrey V Ravetch
Journal:  Nat Immunol       Date:  2014-08       Impact factor: 25.606

Review 8.  A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza.

Authors:  Boopathy Ramakrishnan; Karthik Viswanathan; Kannan Tharakaraman; Vlado Dančík; Rahul Raman; Gregory J Babcock; Zachary Shriver; Ram Sasisekharan
Journal:  Trends Microbiol       Date:  2016-10-14       Impact factor: 17.079

9.  The cytokine response of U937-derived macrophages infected through antibody-dependent enhancement of dengue virus disrupts cell apical-junction complexes and increases vascular permeability.

Authors:  Henry Puerta-Guardo; Arturo Raya-Sandino; Lorenza González-Mariscal; Victor H Rosales; José Ayala-Dávila; Bibiana Chávez-Mungía; Daniel Martínez-Fong; Fernando Medina; Juan E Ludert; Rosa María del Angel
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

10.  Dengue Patients with Early Hemorrhagic Manifestations Lose Coordinate Expression of the Anti-Inflammatory Cytokine IL-10 with the Inflammatory Cytokines IL-6 and IL-8.

Authors:  Felipe Campos de Melo Iani; Sérgio Caldas; Myrian Morato Duarte; Ana Luisa Furtado Cury; Alzira Batista Cecílio; Pedro Augusto Carvalho Costa; Lis R Antonelli; Kenneth J Gollob
Journal:  Am J Trop Med Hyg       Date:  2016-05-02       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.